Incidence, mortality and survival analyses for carcinosarcoma from 1975 to 2018: an epidemiological study

Carcinosarcoma (CS) is a rare malignant tumor, with little known about its epidemiological features in literature. This study aimed to report the largest and latest analysis on the incidence, mortality and survival of CS. Data of CS from the Surveillance, Epidemiology and End Results (SEER) database (SEER-9 incidence database and SEER-9 incidence-based mortality database) were retrieved and assessed. Incidence, mortality and survival analyses were performed using the SEER*Stat software. We used annual percentage change (APC) to evaluate the trends in incidence and mortality. The results showed that the incidence rate of CS increased from 0.36/100,000 to 0.83/100,000, with an APC of 3.4%, from 1975 to 2018. Its mortality rate followed a similar pattern, with an APC increase of 3.2% from 0.07/100,000 in 1975 to 0.54/100,000 in 2018. Most CS cases were reported to be from the female genital system. The 5-year survival rate of all patients was 34.9%. CS is an aggressive tumor with increasing incidence and mortality trends. This tumor, especially CS in the female genital system, should no longer be considered a rare tumor. This research broads our knowledge of CS and provides important insights for clinicians.

Carcinosarcoma; Epidemiology; Incidence; Mortality; Survival

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Virchow R. Die krankhaften Geschwülste. 1st ed. Springer: Berlin. 1863.

[3] Wick MR, Swanson PE. Carcinosarcomas: current perspectives and an historical review of nosological concepts. Seminars in Diagnostic Pathology. 1993; 10: 118–127.

[4] Lin S, Liu C, Tao Z, Zhang J, Hu X. Clinicopathological characteristics and survival outcomes in breast carcinosarcoma: a SEER population-based study. Breast. 2020; 49: 157–164.

[5] Rauh-Hain JA, Diver EJ, Clemmer JT, Bradford LS, Clark RM, Growdon WB, et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecologic Oncology. 2013; 131: 46–51.

[6] Pang A, Carbini M, Moreira AL, Maki RG. Carcinosarcomas and related cancers: tumors caught in the act of epithelial-mesenchymal transition. Journal of Clinical Oncology. 2018; 36: 210–216.

[7] Arrastia CD, Fruchter RG, Clark M, Maiman M, Remy JC, Macasaet M, et al. Uterine carcinosarcomas: incidence and trends in management and survival. Gynecologic Oncology. 1997; 65: 158–163.

[8] Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. International Journal of Gynecological Cancer. 2014; 24: S55–60.

[9] Qian ZJ, Jin MC, Meister KD, Megwalu UC. Pediatric thyroid cancer incidence and mortality trends in the United States, 1973–2013. JAMA Otolaryngology—Head & Neck Surgery. 2019; 145: 617.

[10] Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013; 119: 1149–1158.

[11] Lewis DR, Siembida EJ, Seibel NL, Smith AW, Mariotto AB. Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975–2016. Cancer. 2021; 127: 4277–4286.

[12] Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, et al. Cancer survival: an overview of measures, uses, and interpretation. Journal of the National Cancer Institute. Monographs. 2014; 2014: 145–186.

[13] McCluggage WG, McManus DT, Lioe TF, Hill CM. Uterine carcinosarcoma in association with tamoxifen therapy. British Journal of Obstetrics and Gynaecology. 1997; 104: 748–750.

[14] Palda VA, Goel V, Sawka CA. The rise of tamoxifen: temporal and geographical trends of tamoxifen use in Ontario. Breast Cancer Research and Treatment. 1997; 43: 33–41.

[15] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022; 72: 7–33.

[16] Matsuo K, Ross MS, Machida H, Blake EA, Roman LD. Trends of uterine carcinosarcoma in the United States. Journal of Gynecologic Oncology. 2018; 29: e22.

[17] Ersek JL, Symanowski JT, Han Y, Howard A, Dumas K, Ahrens W, et al. Pulmonary carcinosarcoma: a surveillance, epidemiology, and end results (SEER) analysis. Clinical Lung Cancer. 2020; 21: 160–170.

[18] Argüelles Salido E, Travado Soria P, Pérez Espejo MP, Rodríguez Corchero J, Medina López RA, Pena Outeiriño JM. Carcinosarcoma of the bladder: report of our cases and review of the literature. Actas Urologicas Españolas. 2004; 28: 262–268. (In Spanish)

[19] Marco FD, Piombino E, Portale TR, Magro G, Pesce A. Carcinosarcoma of the stomach: a rare tumor for an unusual localization. Review of the literature. Turkish Journal of Gastroenterology. 2019; 30: 1066–1069.

[20] Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97: 934–959.

[21] Wu SG, Chen XT, Zhang WW, Sun JY, Li FY, He ZY, et al. Survival in signet ring cell carcinoma varies based on primary tumor location: a surveillance, epidemiology, and end results database analysis. Expert Review of Gastroenterology & Hepatology. 2018; 12: 209–214.

[22] Bonazzi VF, Kondrashova O, Smith D, Nones K, Sengal AT, Ju R, et al. Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer. Genome Medicine. 2022; 14: 3.